What is Magenta?
Magenta specializes in the engineering and manufacturing of advanced medical devices, most notably the Elevate percutaneous Left Ventricular Assist Device (pLVAD). This technology is engineered to provide essential hemodynamic support for patients undergoing high-risk coronary interventions or those suffering from acute cardiogenic shock. By focusing on the intersection of mechanical circulatory support and critical care, Magenta addresses a vital gap in hospital-based cardiac treatment. The company's market position is defined by its commitment to improving patient outcomes in complex clinical scenarios, providing healthcare professionals with the tools necessary to manage severe cardiovascular instability effectively.
How much funding has Magenta raised?
Magenta has raised a total of $160M across 2 funding rounds:
Other Financing Round
$55M
Other Financing Round
$105M
Other Financing Round (2023): $55M with participation from OrbiMed and New Enterprise Associates
Other Financing Round (2024): $105M led by Novo Holdings, Viking Global Investors, and RA Capital Management
Key Investors in Magenta
Novo Holdings
A Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on long-term investments in life sciences.
Viking Global Investors
A global investment firm utilizing research-intensive, fundamental analysis to select public and private equity interests across diverse geographies.
RA Capital Management
A multi-stage investment manager focused on evidence-based investing in healthcare and life science companies, supported by their internal TechAtlas research think tank.
What's next for Magenta?
With the recent influx of capital, Magenta is expected to scale its operational capacity and expand its clinical trial footprint. The strategic focus will likely shift toward optimizing the manufacturing processes for the Elevate pLVAD and navigating the regulatory pathways required for broader market adoption. As the company transitions into this next phase of growth, the emphasis will remain on clinical validation and the integration of its devices into standard-of-care protocols for cardiac centers globally. This funding round provides the necessary runway to sustain long-term research and development, ensuring that Magenta remains at the forefront of life-saving medical innovation.
See full Magenta company page
